Rare Disease Day is less than a week away

On February 28th, the rare disease community comes together to raise awareness of the impact of rare diseases on millions. For the 30 million people experiencing a rare disease, life can be filled with questions. Identifying possible symptoms of a rare disease often sparks a “diagnostic odyssey” that can stretch over many years. Fortunately, as…

Read More

Leading with quality: Data sharing

Only through real and meaningful data sharing can the field of genetics reach its full potential. At Invitae, we’re dedicated to improving medicine not just by sharing segments of our data, but by sharing all variants, classifications and evidence. That’s not yet the industry standard—but it is at Invitae. Among other activities, Invitae has played…

Read More

Exciting year ahead for genetic testing

2016 was an exciting year for genetics, and an important one for Invitae. Last year we provided genetic testing to more people than ever before, reduced our turnaround times, and expanded our test menu to over 1,100 genes. We also improved patient access to our testing by adding new insurance payers to secure coverage for…

Read More

Major expansion of pediatric, neurological, and rare disease offerings

Invitae has launched 24 new and expanded 19 genetic test panels, allowing clinicians to gain information on 183 new genes with clinical and diagnostic significance. This launch represents a significant expansion of the company’s pediatric, neurological, and rare disease offerings, which include tests for genes associated with epilepsy, developmental disorders, overgrowth syndromes, and skeletal disorders, as…

Read More

New leader in prostate cancer genetic testing

Genetic testing for prostate cancer has noticeably increased since the publication of landmark data showing testing may be underutilized when screening for and treating the second most common cancer in men. Invitae’s panel is the most comprehensive and affordable genetic test available to urologists and oncologists who treat men with prostate cancer, establishing the company as a…

Read More

Behind the Seizure™ program launch

Last week at the American Epilepsy Society meeting in Houston, we launched a very exciting new program with BioMarin Pharmaceutical Inc. Behind the Seizure™ is a no charge epilepsy gene panel testing program for children age 3 years who experienced their first unprovoked seizures after the age of 2 years and meet certain clinical criteria. In…

Read More

Invitae to add to pediatric and neurology offerings

We listened to your requests and are pleased to announce that in December we will be adding 27 new diagnostic panels and updating 19 current panels for pediatric and neurologic conditions. With this latest expansion of test offerings, Invitae provides clinicians, patients, and managed care partners with high-quality information across a wide variety of hereditary…

Read More